Research Use Only - Not for human consumption. 18+ only.
Clinical TrialsKhavinson BioregulatorsSubcutaneous

Prostamax

Prostate gland bioregulator peptide from the Khavinson series. Short peptide (2-4 amino acids) that targets specific tissue for gene expression regulation and organ health optimization.

Research Status

Clinical Trials

Limited Clinical Data

For research purposes only. Not approved for human use. Not medical advice.

Research Areas

Supports prostate gland health and function
May promote normal urinary flow patterns
Supports healthy prostate tissue gene expression
May help maintain prostate-specific antigen levels
Supports healthy inflammatory response in prostate tissue

Side Effects

Local injection site reactions
UncommonMild

Mild redness, swelling, or itching at the injection site may occur. Typically resolves within 1-2 hours. Rotate injection sites to minimize recurrence. Apply ice if swelling persists.

Allergic reaction
RareSerious

Anaphylaxis or severe allergic response is rare but possible with any peptide. Symptoms include difficulty breathing, facial swelling, or severe rash. Seek immediate medical attention if these occur. Individuals with known peptide allergies should avoid use.

Mild headache
UncommonMild

Transient headache may occur within hours of injection. Typically self-resolving. Ensure adequate hydration and rest. If persistent, discontinue and consult a healthcare provider.

Nausea or mild gastrointestinal discomfort
UncommonMild

Mild nausea or stomach discomfort may occur, particularly if injected on an empty stomach. Eating a light meal before injection may help. Symptoms typically resolve within a few hours.

Lipodystrophy (localized fat loss or thickening)
UncommonModerate

Repeated injections at the same site can cause localized fat loss (lipoatrophy) or fat thickening (lipohypertrophy). Prevent by rotating injection sites systematically. If lipodystrophy develops, avoid injecting in that area for several months.

Dosing Reference

ParameterValue
Dose range10-20 mcg
Frequency1x daily
TimingMorning, sublingual or subcutaneous
RouteSubcutaneous

Khavinson bioregulator peptide. Limited Western clinical trials; widely used in Russia and Eastern Europe. Start at lower end (10 mcg) and assess response over 4-6 weeks before adjusting. For research purposes only.

Research disclaimer

Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.

Reconstitution Guide

Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution

Do not shake the vial vigorously; gentle swirling prevents peptide degradation

Discard immediately if the solution appears cloudy, discolored, or contains visible particles

Use within 30 days of reconstitution when stored at 2–8°C

Do not freeze the reconstituted solution; freezing may denature the peptide

Use the PeptideVolt reconstitution calculator for your exact concentration

Use the PeptideVolt reconstitution calculator for your exact concentration

Molecular and Pharmacological Data

Prostamax is a short peptide bioregulator (2-4 amino acids) derived from prostate tissue that is proposed to regulate gene expression and support normal prostate gland function through tissue-specific signaling. The peptide is theorized to interact with cellular receptors and transcription factors to promote healthy prostate tissue homeostasis and normal urinary function. Research on Khavinson bioregulators suggests they may modulate inflammatory pathways and support organ-specific regenerative processes, though the precise molecular mechanism in human prostate tissue remains incompletely characterized.

Tissue-Specific Gene Regulation

Bioregulator peptides are proposed to bind to specific cellular receptors in prostate tissue and influence transcription factor activity, thereby modulating expression of genes involved in prostate cell differentiation and function.

Inflammatory Modulation

Khavinson peptides may influence inflammatory signaling pathways in prostate tissue, potentially supporting normal inflammatory responses and tissue homeostasis.

Cellular Differentiation and Proliferation

Short peptide bioregulators are theorized to support normal cellular differentiation patterns in prostate epithelial cells and regulate cell cycle progression.

  • Prostamax is part of the Khavinson bioregulator series, a class of short peptides derived from animal organ tissues
  • Bioregulator peptides are proposed to work through tissue-specific mechanisms rather than systemic hormonal pathways
  • Clinical evidence in Western literature is limited; most research and clinical use is documented in Russian and Eastern European medical literature
  • The exact amino acid sequence and molecular targets of Prostamax are not publicly disclosed in peer-reviewed literature

Track your Prostamax research

Free account. No credit card required.

Start Free

Browse the Research Library

40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.

View all peptides

Research Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Prostamax is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.